share_log

EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

Benzinga Real-time News ·  Feb 16, 2023 00:02

EF Hutton analyst Michael King maintains Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment